AMRN($290M) has a higher market cap than GTBP($15.3M). AMRN YTD gains are higher at: -1.111 vs. GTBP (-56.139). GTBP has higher annual earnings (EBITDA): -4.51M vs. AMRN (-43.2M). GTBP has less debt than AMRN: GTBP (0) vs AMRN (5.26M). AMRN has higher revenues than GTBP: AMRN (186M) vs GTBP (0).

	AMRN	GTBP	AMRN / GTBP
Capitalization	290M	15.3M	1,895%
EBITDA	-43.2M	-4.51M	959%
Gain YTD	-1.111	-56.139	2%
P/E Ratio	N/A	0.07	-
Revenue	186M	0	-
Total Cash	315M	N/A	-
Total Debt	5.26M	0	-

FUNDAMENTALS RATINGS

AMRN vs GTBP: Fundamental Ratings

	AMRN	GTBP
OUTLOOK RATING 1..100	93	2
VALUATION overvalued / fair valued / undervalued 1..100	80 Overvalued	35 Fair valued
PROFIT vs RISK RATING 1..100	100	100
SMR RATING 1..100	92	100
PRICE GROWTH RATING 1..100	59	89
P/E GROWTH RATING 1..100	100	22
SEASONALITY SCORE 1..100	50	50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBP's Valuation (35) in the null industry is somewhat better than the same rating for AMRN (80) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew somewhat faster than AMRN’s over the last 12 months.

GTBP's Profit vs Risk Rating (100) in the null industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew similarly to AMRN’s over the last 12 months.

AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as GTBP (100) in the null industry. This means that AMRN’s stock grew similarly to GTBP’s over the last 12 months.

AMRN's Price Growth Rating (59) in the Pharmaceuticals Other industry is in the same range as GTBP (89) in the null industry. This means that AMRN’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's P/E Growth Rating (22) in the null industry is significantly better than the same rating for AMRN (100) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew significantly faster than AMRN’s over the last 12 months.

TECHNICAL ANALYSIS

Technical Analysis

	AMRN	GTBP
RSI ODDS (%)	N/A	2 days ago 90%
Stochastic ODDS (%)	2 days ago 77%	2 days ago 87%
Momentum ODDS (%)	2 days ago 90%	2 days ago 80%
MACD ODDS (%)	2 days ago 80%	2 days ago 90%
TrendWeek ODDS (%)	2 days ago 75%	2 days ago 90%
TrendMonth ODDS (%)	2 days ago 85%	2 days ago 78%
Advances ODDS (%)	4 days ago 73%	2 days ago 81%
Declines ODDS (%)	2 days ago 85%	5 days ago 90%
BollingerBands ODDS (%)	N/A	2 days ago 90%
Aroon ODDS (%)	2 days ago 78%	2 days ago 90%

COMPARISON

Comparison

Sep 12, 2026

Stock price -- (AMRN: $13.80 vs. GTBP: $8.61)

Brand notoriety: AMRN: Notable vs. GTBP: Not notable

AMRN represents the Pharmaceuticals: Major, while GTBP is part of the Biotechnology industry

Current volume relative to the 65-day Moving Average: AMRN: 59% vs. GTBP: 80%

Market capitalization -- AMRN: $290.21M vs. GTBP: $15.34M

AMRN [@Pharmaceuticals: Major] is valued at $290.21M. GTBP’s [@Biotechnology] market capitalization is $15.34M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $72.83K to $994.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Pharmaceuticals: Major] industry is $193.44B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green while GTBP’s FA Score has 1 green FA rating(s).

AMRN’s FA Score: 0 green, 5 red.
GTBP’s FA Score: 1 green, 4 red.

According to our system of comparison, GTBP is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while GTBP’s TA Score has 4 bullish TA indicator(s).

AMRN’s TA Score: 4 bullish, 3 bearish.
GTBP’s TA Score: 4 bullish, 6 bearish.

According to our system of comparison, AMRN is a better buy in the short-term than GTBP.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а +1.25% price change this week, while GTBP (@Biotechnology) price change was -94.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.36%. For the same industry, the average monthly price growth was -3.99%, and the average quarterly price growth was +5.78%.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Industries' Descriptions

@Pharmaceuticals: Major (-4.36% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three

AMRN

Daily Signal:

Gain/Loss:

GTBP

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

Interesting Tickers

MFs / NAME	Price $	Chg $	Chg %
		1 Day
EQPGX	29.37	N/A	N/A
Fidelity Advisor Equity Growth I
EMAAX	18.52	N/A	N/A
Gabelli Entpr Mergers & Acquisitions A
TIOPX	17.88	N/A	N/A
Nuveen International Opps Prem
RGPAX	24.32	N/A	N/A
RBC Global Opportunities A
PMIVX	11.57	N/A	N/A
Franklin Multi-Asset Income R6

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with SLGL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then SLGL could also see price increases.

Ticker / NAME	Correlation To GTBP	1D Price Change %
GTBP	100%	+39.32%
SLGL - GTBP	33% Loosely correlated	-1.27%
AMRN - GTBP	33% Poorly correlated	-1.71%
MDGL - GTBP	32% Poorly correlated	+0.26%
VKTX - GTBP	31% Poorly correlated	-0.47%
BMEA - GTBP	29% Poorly correlated	+2.35%
More